2016 Drug Development Medical Records 
pharmaphorum
JUNE 18, 2021
Patient recruitment and retention in clinical trials have long been significant challenges for drug developers. Four years before the pandemic, in 2016, Wout set up Deep 6 AI. However, Deep 6 AI has developed cutting?edge changing treatment. edge technology that pulls insights from this chaotic data in minutes.
FDA Law Blog: Biosimilars
FEBRUARY 5, 2024
The Draft Guidance emphasizes that study team should not answer the questions based on observation or even on existing medical records. When finalized, the Draft Guidance will take the place of the 2016 guidance Collection of Race and Ethnicity Data in Clinical Trials. The comment period ends on April 29, 2024.
European Pharmaceutical Review
DECEMBER 14, 2023
Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. This may come as a surprise because RCTs are seen as the gold standard of drug development, and they certainly have their place. Article (Samantha Lane): How can evidence-based medicine (EBM) methodology support drug withdrawals?
Expert insights. Personalized for you.
52 
Let's personalize your content